Intranasal Leukemia Inhibitory Factor Attenuates Gliosis and Axonal Injury and Improves Sensorimotor Function after a Mild Pediatric Traumatic Brain Injury

Veera D'Mello, Malini Subramaniam, Aditya Paul Bhalla, Sherlyn Saavedra, Ofri Leiba, Steven W. Levison

Research output: Contribution to journalArticlepeer-review

Abstract

Leukemia inhibitory factor (LIF) is a neuroprotective cytokine that is essential for appropriate glial responses, remyelination, and preservation of neuronal conductance after injury. The intranasal route for delivery of therapeutics to the central nervous system is of particular interest given that it bypasses the blood-brain barrier and peripheral clearance systems. We explored the possibility that LIF might improve neurological function when administered intranasally during the acute phase in a pediatric model of mild traumatic brain injury (mTBI). We tested two doses of LIF and evaluated behavioral outcomes. Here, we show that acute 40-ng intranasal LIF treatment twice a day for 3 days attenuates astrogliosis and microgliosis, protects against axonal damage, significantly improves sensorimotor function, and is well tolerated without detrimental effects on growth. Altogether, our studies provide pre-clinical evidence for the use of acute intranasal LIF treatment as a viable therapeutic for pediatric cases of mTBIs.

Original languageEnglish (US)
Pages (from-to)236-250
Number of pages15
JournalNeurotrauma Reports
Volume4
Issue number1
DOIs
StatePublished - Apr 1 2023
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience

Keywords

  • astrogliosis
  • blood-brain barrier
  • microgliosis
  • neurotrauma
  • traumatic axonal injury

Fingerprint

Dive into the research topics of 'Intranasal Leukemia Inhibitory Factor Attenuates Gliosis and Axonal Injury and Improves Sensorimotor Function after a Mild Pediatric Traumatic Brain Injury'. Together they form a unique fingerprint.

Cite this